{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:05:20Z","timestamp":1780484720599,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1989,1,1]],"date-time":"1989-01-01T00:00:00Z","timestamp":599616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1989]]},"DOI":"10.1007\/bf00589890","type":"journal-article","created":{"date-parts":[[2004,11,26]],"date-time":"2004-11-26T18:42:23Z","timestamp":1101494543000},"page":"445-449","source":"Crossref","is-referenced-by-count":107,"title":["Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients"],"prefix":"10.1007","volume":"99","author":[{"given":"F.","family":"Mesotten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Suy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pietquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","unstructured":"American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders (edn III) Washington DC"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0447.1977.tb00147.x","volume":"55","author":"L Ansoms","year":"1977","unstructured":"Ansoms L, De Backer-Dierick G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: doubleblind placebo-controlled evaluation of the value of pipamperone. Acta Psychiatr Scand 55:116?122","journal-title":"Acta Psychiatr Scand"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ddr.430150107","volume":"15","author":"F Awouters","year":"1988","unstructured":"Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 15:61?73","journal-title":"Drug Dev Res"},{"key":"CR4","unstructured":"Castelao JF, Ferreira F (1989) Risperidone (R 64766) in the treatment of therapy-resistant chronic psychotic patients: an open dose-finding study. Schizophr Res (in press)"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00428197","volume":"85","author":"DLS Ceulemans","year":"1985","unstructured":"Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM Janssen PAJ (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329?332","journal-title":"Psychopharmacology"},{"key":"CR6","first-page":"157","volume":"76","author":"R Deberdt","year":"1976","unstructured":"Deberdt R (1976) Pipamperone in the treatment of behaviour disorders. A large scale multicentre evaluation. Acta Psychiatr Belg 76:157?166","journal-title":"Acta Psychiatr Belg"},{"key":"CR7","first-page":"685","volume":"244","author":"PAJ Janssen","year":"1988","unstructured":"Janssen PAJ, Niemegeers CJE, Awouters FHL, Schellekens KHL, Megens AAHP, Meert TP (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685?693","journal-title":"J Pharmacol Exp Ther"},{"key":"CR8","first-page":"600","volume":"27","author":"JE Leysen","year":"1985","unstructured":"Leysen JE, Gommeren W, Van Gompel P, Wijnants J, Janssen PFM, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting serotonin-S2 antagonist. Mol Pharmacol 27:600?611","journal-title":"Mol Pharmacol"},{"key":"CR9","first-page":"661","volume":"247","author":"JE Leysen","year":"1988","unstructured":"Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661?670","journal-title":"J Pharmacol Exp Ther"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00442251","volume":"97","author":"TF Meert","year":"1989","unstructured":"Meert TF, de Haes P, Niemegeers CJE (1989) Risperidone (R 64766), a potent and complete LSD-antagonist in drug discrimination by rats. Psychopharmacology 97:206?212","journal-title":"Psychopharmacology"},{"key":"CR11","first-page":"493","volume":"95","author":"AAHP Megens","year":"1988","unstructured":"Megens AAHP, Awouters FHL, Niemegeers CJE (1988) Differential effects of the new antipsychotic risperidone on large and small motor movements in rats. Psychopharmacology 95: 493?496","journal-title":"Psychopharmacology"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799?812","journal-title":"Psychol Rep"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ddr.430080124","volume":"8","author":"AJM Reyntjens","year":"1986","unstructured":"Reyntjens AJM, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8:205?211","journal-title":"Drug Dev Res"},{"key":"CR14","unstructured":"Roose K, Gelders YG, Heylen SLE (1989) Risperidone (R 64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg (in press)"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212:11?19","journal-title":"Acta Psychiatr Scand"},{"key":"CR16","first-page":"201","volume":"23","author":"T Putten Van","year":"1987","unstructured":"Van Putten T, Marder SR, Mintz J (1987) The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharm Bull 23:201?205","journal-title":"Psychopharm Bull"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00589890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00589890\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00589890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T23:20:32Z","timestamp":1554420032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00589890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1989]]}},"alternative-id":["BF00589890"],"URL":"https:\/\/doi.org\/10.1007\/bf00589890","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989]]}}}